FDA Accepts Review of Zogenix's (ZGNX) Zohydro ER NDA for Chronic Pain

Article Stock Quotes (1) Comments (0)

Zogenix, Inc. (Nasdaq: ZGNX) announced today that the U.S. FDA has accepted for review the New Drug Application (NDA) for Zohydro ER™ (hydrocodone bitartrate extended-release capsules), Zogenix's lead investigational product candidate for the treatment of moderate to severe chronic pain. Under the Prescription Drug User Fee Act (PDUFA), the goal for a standard review of an NDA is 10 months from NDA submission, and the FDA has assigned a target action date of March 1, 2013 for the Zohydro ER NDA.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Merck (MRK) Says Efficacy Not Achieved in Preladenant Phase 3s; Will Discontinue
• rue21 (RUE) Will be Acquired by Apax Partners for $42/Share
• Analyst Sees Potential for Omeros' (OMER) OMS824 as FDA Gives Clearance

Create E-mail Alert Related Categories

Corporate News, FDA

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?